Arcutis Biotherapeutics (ARQT) Tmuɣli n wazal
Ṛṛbem n lḥedd$26.92Yettwalemmaḍ 25 Sep 2026 19:59 UTC
Beddel+2.47%
Asnulfu n AI: ARQT
AI tessawal ɣef timaqsiṭ n wazal i wass n tnekkit d-iteddun, taggara n yimal akked taggara n waggʷas. Asnifel yettwamḍen seg wazal aneggaru. Aya d tinineḍ n tḥisabt, ma tga ara timsisi n usihel.
Asref n 6 isggʷasn ineggura
Premium tessaɣ-d iswiyat n tɣara n AI i wass, amalas d waggʷas n yiwen i uḍris-a akk d yisɣunan niḍen.
Serreḥ Premium🔒 Tazmilt n usenfar
Amezruy n tmuɣliyin — akk tmuɣliyin n zik akked wazal n tnekkit — d akcum n Premium.
Serreḥ PremiumƔef tneɣlaft-a
Arcutis Biotherapeutics, Inc. operates as a biopharmaceutical company specializing in the development of treatments for unmet medical needs in immune-mediated diseases and conditions. The company serves the U.S. healthcare sector.
